Login
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc.

cullinantherapeutics.com

What Do They Do?

Develops experimental medicines for autoimmune diseases and cancer, including blood and lung cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +2% (Loss)
vs −$50.6M in Q3 FY2025

Broader disease focus The older reports center on targeted cancer drug development across different treatment approaches; the latest report also focuses on autoimmune diseases and places T cell engagers at the center of its strategy.

The program's treatment focus The program was initially aimed at relapsed B-cell non-Hodgkin lymphoma; the latest report says development there was discontinued and the candidate is being developed exclusively for autoimmune diseases.

Who Do They Compete With?

Competes with Amgen, Roche Holdings, AstraZeneca, Merck &, Novartis, GSK, Xencor, Zenas BioPharma, Eli Lilly and, Climb Bio, Regeneron Pharmaceuticals, Candid Therapeutics, Ouro Medicines, Astellas Pharma, Daiichi Sankyo, Aptose Biosciences, Veraxa Biotech, Hemogenyx Pharmaceuticals, Senti Biosciences, and Aptevo Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support